MedImmune parent, Amgen launch partnership – Gazette.Net: Maryland Community News Online


Telegraph.co.uk

MedImmune parent, Amgen launch partnership
Gazette.Net: Maryland Community News Online
AstraZeneca is to lead the development and commercial strategy of three candidates, AMG 139, AMG 157 and AMG 181, which are being studied to treat Crohn's disease, asthma and ulcerative colitis, respectively. Amgen will spearhead efforts regarding
Amgen and AstraZeneca Announce Collaboration to Jointly Develop and PR Newswire (press release)
Big Pharma Buys Access To This Promising Biotech PipelineMotley Fool UK
AstraZeneca, Amgen enter into development and commercialization agreementPharmaceutical Business Review
FierceBiotech –Washington Business Journal –Reuters UK
all 11 news articles »

View full post on asthma – Google News